Send to

Choose Destination

Prostate cancer chemoprevention agents exhibit selective activity against early stage prostate cancer cells.

Author information

Division of Hematology/Oncology, Department of Medicine, Northwest University Medical School and the Robert H. Lurie Cancer Center of Northwestern University, Chicago, USA.


Preclinical models for the identification of prostate cancer chemoprevention agents are lacking. Based upon the notion that clinically useful chemoprevention agents should exhibit selective activity against early stage disease, studies were undertaken to assess whether chemoprevention agents selectively inhibited the growth of early stage prostate cancer, as compared to late stage cancer. First, a series of cell and molecular studies were performed, which, when taken together, validated the use of a panel of prostate cell lines as a model of the different stages of carcinogenesis. Next, therapeutic responsiveness to ten different cytotoxic or chemoprevention agents was evaluated. Chemoprevention agents exhibited selective activity against normal and early transformed prostate tissue, whereas cytotoxic agents were non-specific. Selective activity against early versus advanced prostate cancer cells is identified as a potential screening method for chemoprevention agents.Prostate Cancer and Prostatic Diseases (2001) 4, 81-91.

Free full text

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center